Association of ADIPOQ variants and heart failure in an Italian population

Silvana Pileggi, Simona Barlera, Enrico Nicolis, Luisa Crociati, Silvia Pietri, Maria Grazia Franzosi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives: Adiponectin has insulin-sensitizing, anti-inflammatory and anti-atherogenic properties. There are few and controversial data on the role of ADIPOQ variants in heart failure (HF) pathogenesis. We planned this large association study to investigate the potential association of four selected ADIPOQ polymorphisms with HF in a population of Italian origin. Methods: We genotyped 1173 cases with symptomatic HF and 1136 controls for alleles rs17300539, rs266729, rs1501299 and rs2241766. Cases were patients enrolled in the GISSIHeart Failure genetic sub-study, with a long-term follow up (median 3.9 years). Controls were blood donors with no history of diabetes or cardiovascular disease (CVD). Genotype and allele frequencies of the four single nucleotide polymorphisms (SNPs) were compared between the two groups. Results: Clinical characteristics were significantly different between HF patients and controls. No significant differences were reported in the allelic and genotypic distribution, with the exception of rs266729 G allele, which showed a significant association with an increased risk of HF [odds ratio (OR) = 1.26; 95% confidence interval (CI) = 1.071.48; p = 0.006). We divided the GISSI-HF population according to HF etiology (ischemic and nonischemic) and presence of diabetes. For rs266729 G allele, a significant association with HF was confirmed in both ischemic (OR = 1.29; 95% CI = 1.061.56; p = 0.009) and nonischemic patients (OR = 1.2; 95% CI = 1.021.42; p = 0.03) as well as in nondiabetic patients (OR = 1.25; 95% CI = 1.051.49; p = 0.012). rs2241766 G allele showed a significant reduction of risk of HF in nonischemic (OR = 0.77; 95% CI = 0.620.95; p = 0.02) and diabetic patients (OR = 0.62; 95% CI = 0.450.84; p = 0.0025). Conclusions: We confirm the association between rs266729 G allele and an increased risk of HF and between rs2241766 G allele and decreased risk of HF. Our study extends the knowledge on the influence of ADIPOQ variants on CVD.

Original languageEnglish
Pages (from-to)89-96
Number of pages8
JournalTherapeutic Advances in Cardiovascular Disease
Volume8
Issue number3
DOIs
Publication statusPublished - 2014

Fingerprint

Heart Failure
Population
Alleles
Odds Ratio
Confidence Intervals
Cardiovascular Diseases
Adiponectin
Risk Reduction Behavior
Blood Donors
Gene Frequency
Single Nucleotide Polymorphism
Anti-Inflammatory Agents
Genotype
Insulin

Keywords

  • adiponectin
  • chronic heart failure
  • diabetes
  • etiology
  • single nucleotide polymorphisms

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Pileggi, S., Barlera, S., Nicolis, E., Crociati, L., Pietri, S., & Franzosi, M. G. (2014). Association of ADIPOQ variants and heart failure in an Italian population. Therapeutic Advances in Cardiovascular Disease, 8(3), 89-96. https://doi.org/10.1177/1753944714531063

Association of ADIPOQ variants and heart failure in an Italian population. / Pileggi, Silvana; Barlera, Simona; Nicolis, Enrico; Crociati, Luisa; Pietri, Silvia; Franzosi, Maria Grazia.

In: Therapeutic Advances in Cardiovascular Disease, Vol. 8, No. 3, 2014, p. 89-96.

Research output: Contribution to journalArticle

Pileggi, S, Barlera, S, Nicolis, E, Crociati, L, Pietri, S & Franzosi, MG 2014, 'Association of ADIPOQ variants and heart failure in an Italian population', Therapeutic Advances in Cardiovascular Disease, vol. 8, no. 3, pp. 89-96. https://doi.org/10.1177/1753944714531063
Pileggi, Silvana ; Barlera, Simona ; Nicolis, Enrico ; Crociati, Luisa ; Pietri, Silvia ; Franzosi, Maria Grazia. / Association of ADIPOQ variants and heart failure in an Italian population. In: Therapeutic Advances in Cardiovascular Disease. 2014 ; Vol. 8, No. 3. pp. 89-96.
@article{d498396d880549c6bcaefebd463c1712,
title = "Association of ADIPOQ variants and heart failure in an Italian population",
abstract = "Objectives: Adiponectin has insulin-sensitizing, anti-inflammatory and anti-atherogenic properties. There are few and controversial data on the role of ADIPOQ variants in heart failure (HF) pathogenesis. We planned this large association study to investigate the potential association of four selected ADIPOQ polymorphisms with HF in a population of Italian origin. Methods: We genotyped 1173 cases with symptomatic HF and 1136 controls for alleles rs17300539, rs266729, rs1501299 and rs2241766. Cases were patients enrolled in the GISSIHeart Failure genetic sub-study, with a long-term follow up (median 3.9 years). Controls were blood donors with no history of diabetes or cardiovascular disease (CVD). Genotype and allele frequencies of the four single nucleotide polymorphisms (SNPs) were compared between the two groups. Results: Clinical characteristics were significantly different between HF patients and controls. No significant differences were reported in the allelic and genotypic distribution, with the exception of rs266729 G allele, which showed a significant association with an increased risk of HF [odds ratio (OR) = 1.26; 95{\%} confidence interval (CI) = 1.071.48; p = 0.006). We divided the GISSI-HF population according to HF etiology (ischemic and nonischemic) and presence of diabetes. For rs266729 G allele, a significant association with HF was confirmed in both ischemic (OR = 1.29; 95{\%} CI = 1.061.56; p = 0.009) and nonischemic patients (OR = 1.2; 95{\%} CI = 1.021.42; p = 0.03) as well as in nondiabetic patients (OR = 1.25; 95{\%} CI = 1.051.49; p = 0.012). rs2241766 G allele showed a significant reduction of risk of HF in nonischemic (OR = 0.77; 95{\%} CI = 0.620.95; p = 0.02) and diabetic patients (OR = 0.62; 95{\%} CI = 0.450.84; p = 0.0025). Conclusions: We confirm the association between rs266729 G allele and an increased risk of HF and between rs2241766 G allele and decreased risk of HF. Our study extends the knowledge on the influence of ADIPOQ variants on CVD.",
keywords = "adiponectin, chronic heart failure, diabetes, etiology, single nucleotide polymorphisms",
author = "Silvana Pileggi and Simona Barlera and Enrico Nicolis and Luisa Crociati and Silvia Pietri and Franzosi, {Maria Grazia}",
year = "2014",
doi = "10.1177/1753944714531063",
language = "English",
volume = "8",
pages = "89--96",
journal = "Therapeutic Advances in Cardiovascular Disease",
issn = "1753-9447",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Association of ADIPOQ variants and heart failure in an Italian population

AU - Pileggi, Silvana

AU - Barlera, Simona

AU - Nicolis, Enrico

AU - Crociati, Luisa

AU - Pietri, Silvia

AU - Franzosi, Maria Grazia

PY - 2014

Y1 - 2014

N2 - Objectives: Adiponectin has insulin-sensitizing, anti-inflammatory and anti-atherogenic properties. There are few and controversial data on the role of ADIPOQ variants in heart failure (HF) pathogenesis. We planned this large association study to investigate the potential association of four selected ADIPOQ polymorphisms with HF in a population of Italian origin. Methods: We genotyped 1173 cases with symptomatic HF and 1136 controls for alleles rs17300539, rs266729, rs1501299 and rs2241766. Cases were patients enrolled in the GISSIHeart Failure genetic sub-study, with a long-term follow up (median 3.9 years). Controls were blood donors with no history of diabetes or cardiovascular disease (CVD). Genotype and allele frequencies of the four single nucleotide polymorphisms (SNPs) were compared between the two groups. Results: Clinical characteristics were significantly different between HF patients and controls. No significant differences were reported in the allelic and genotypic distribution, with the exception of rs266729 G allele, which showed a significant association with an increased risk of HF [odds ratio (OR) = 1.26; 95% confidence interval (CI) = 1.071.48; p = 0.006). We divided the GISSI-HF population according to HF etiology (ischemic and nonischemic) and presence of diabetes. For rs266729 G allele, a significant association with HF was confirmed in both ischemic (OR = 1.29; 95% CI = 1.061.56; p = 0.009) and nonischemic patients (OR = 1.2; 95% CI = 1.021.42; p = 0.03) as well as in nondiabetic patients (OR = 1.25; 95% CI = 1.051.49; p = 0.012). rs2241766 G allele showed a significant reduction of risk of HF in nonischemic (OR = 0.77; 95% CI = 0.620.95; p = 0.02) and diabetic patients (OR = 0.62; 95% CI = 0.450.84; p = 0.0025). Conclusions: We confirm the association between rs266729 G allele and an increased risk of HF and between rs2241766 G allele and decreased risk of HF. Our study extends the knowledge on the influence of ADIPOQ variants on CVD.

AB - Objectives: Adiponectin has insulin-sensitizing, anti-inflammatory and anti-atherogenic properties. There are few and controversial data on the role of ADIPOQ variants in heart failure (HF) pathogenesis. We planned this large association study to investigate the potential association of four selected ADIPOQ polymorphisms with HF in a population of Italian origin. Methods: We genotyped 1173 cases with symptomatic HF and 1136 controls for alleles rs17300539, rs266729, rs1501299 and rs2241766. Cases were patients enrolled in the GISSIHeart Failure genetic sub-study, with a long-term follow up (median 3.9 years). Controls were blood donors with no history of diabetes or cardiovascular disease (CVD). Genotype and allele frequencies of the four single nucleotide polymorphisms (SNPs) were compared between the two groups. Results: Clinical characteristics were significantly different between HF patients and controls. No significant differences were reported in the allelic and genotypic distribution, with the exception of rs266729 G allele, which showed a significant association with an increased risk of HF [odds ratio (OR) = 1.26; 95% confidence interval (CI) = 1.071.48; p = 0.006). We divided the GISSI-HF population according to HF etiology (ischemic and nonischemic) and presence of diabetes. For rs266729 G allele, a significant association with HF was confirmed in both ischemic (OR = 1.29; 95% CI = 1.061.56; p = 0.009) and nonischemic patients (OR = 1.2; 95% CI = 1.021.42; p = 0.03) as well as in nondiabetic patients (OR = 1.25; 95% CI = 1.051.49; p = 0.012). rs2241766 G allele showed a significant reduction of risk of HF in nonischemic (OR = 0.77; 95% CI = 0.620.95; p = 0.02) and diabetic patients (OR = 0.62; 95% CI = 0.450.84; p = 0.0025). Conclusions: We confirm the association between rs266729 G allele and an increased risk of HF and between rs2241766 G allele and decreased risk of HF. Our study extends the knowledge on the influence of ADIPOQ variants on CVD.

KW - adiponectin

KW - chronic heart failure

KW - diabetes

KW - etiology

KW - single nucleotide polymorphisms

UR - http://www.scopus.com/inward/record.url?scp=84904753058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904753058&partnerID=8YFLogxK

U2 - 10.1177/1753944714531063

DO - 10.1177/1753944714531063

M3 - Article

AN - SCOPUS:84904753058

VL - 8

SP - 89

EP - 96

JO - Therapeutic Advances in Cardiovascular Disease

JF - Therapeutic Advances in Cardiovascular Disease

SN - 1753-9447

IS - 3

ER -